Nektar Therapeutics - Common Stock (NKTR)
$0.87
0.03 (3.02%)
NKTR Stock Quote Delayed 30 Minutes
NKTR Stock Earnings: Nektar Therapeutics Misses EPS, Beats Revenue for Q2 2024
NKTR stock results show that Nektar Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
160.00M
PE Ratio
-1.04
EPS
-0.84
Volume (Avg. Vol.)
2.80M
Day's Range
$0.80 - $0.92
52-Week Range
$0.65 - $1.93
Dividend & Yield
N/A (N/A)
NKTR Stock Predictions, Articles, and Nektar Therapeutics - Common Stock News
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start off trading on Friday with a breakdown of the biggest pre-market stock movers worth keeping an eye on!
Why is Nektar Therapeutics (NKTR) Stock Down Today?
Nektar Therapeutics is down big today after ending some of its clinical trials. What's going on with NKTR stock?
3 Big Stock Charts for Friday: Symantec, Vertex Pharmaceuticals and Nektar Therapeutics
Stock charts of VRTX, NKTR and SYMC are going to end the trading week knocking on the door of major moves.
3 Big Stock Charts for Friday: Nektar Therapeutics, Waters and A.O. Smith
As we move into the weekend, the stock charts of AOS, NKTR and WAT should be on your radar.
Nektar Therapeutics Stock Is a Buy After a Major Market Misread
Sellers dominated the trading action on Nektar stock after its preliminary clinical results. Over-reaction or justified selling? The market simply did not understand the results, hurting the NKTR stock price.
Why Bristol-Myers Squibb Company Shares Are Down Today
Bristol-Myers Squibb Company (BMY) shares were sliding as the company's collaboration cancer drug with Nektar Therapeutics (NKTR) did not impress investors.
Why Nektar Therapeutics Shares Are Plunging Today
Nektar Therapeutics (NKTR) took a heavy hit on Monday following the release of preliminary results from a recent clinical trial.
Nektar Therapeutics Stock Is Risky But Offers Big Reward
Nektar Therapeutics pulled back in recent weeks, and that is a good thing. Valuations are stretched, but the upside in NKTR stock is high if management delivers.
3 Stocks to Watch on Friday: Alphabet Inc (GOOG, GOOGL), Nektar Therapeutics (NKTR) and Solaredge Technologies Inc (SEDG)
Alphabet Inc (GOOG,GOOGL) is fixing latency issues with Google Home Max, while Nektar Therapeutics (NKTR) and Solaredge Technologies Inc (SEDG) reported earnings.
Stocks Weak Amid Fed Hawkishness on Rate Hikes
In the end, the Dow lost a fraction, the S&P gave back 0.2%, the Nasdaq gained a fraction and the Russell 2000 finished the day 0.5% lower.
Is Now the Time to Buy Into These 5 Biotech ETFs?
After a painful 2016, biotech stocks are recovering this year. What lies ahead? Let's look at 5 biotech ETFs to find out
16 Pharmaceuticals Stocks to Sell Now
The overall ratings of 16 Pharmaceuticals stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
